The Federal Trade Commission (FTC) has initiated a major overhaul of the Express Scripts business model. A landmark settlement will compel Express Scripts, a subsidiary of Cigna Group, to calculate patient costs based on net prices instead of list prices. This agreement mandates the passing of rebates to the end consumer and enhances pricing transparency, thereby accelerating the industry's transition towards a "net-price pharmacy channel."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.